B+
Bull case
30%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
AZTA
AzentaFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
-0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+21.4
Score
AI commentary
Primary-source tone turned materially weaker on May 5-8, 2026 as Azenta reported a Q2 miss, cut FY26 organic growth, margin, and free-cash-flow expectations, and then confirmed in the 10-Q that the B Medical buyer had not secured financing by March 31. Using the packet's anchor, shares closed at $18.57 on May 7, 2026, well below the roughly mid-$24 level referenced in immediate post-release coverage, suggesting the negative reaction largely held through the T+3 follow-up. Fresh analyst revision evidence was thin in checked sources, so this remains a cautious monitoring setup rather than a high-conviction rebound call.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-05catalystQ2 miss and FY26 guidance reset keep near-term pressure on the setupHigh impact
Azenta's May 5 earnings release showed fiscal Q2 revenue of $145 million, organic revenue down 3% year over year, adjusted EBITDA margin of 5.4%, and a FY26 reset to roughly down 2% to up 1% organic growth with weaker margin and free-cash-flow expectations; management also pushed the long-range plan to 2029 from 2028 [#8-K-2026-05-05].
2026-05-08eventThe March 31 10-Q confirmed the B Medical sale financing problem and added downside contingency riskMedium impact
The 10-Q said buyer Thelema had not secured financing by March 31, 2026, the transaction did not close, either party may terminate the agreement, and Azenta would retain $5.0 million of the $9.0 million deposit as a break-up fee if terminated; the filing also warned prolonged delay or failure could dilute results and distract management from the core SMS and Multiomics businesses [#10-Q-2026-05-08].
2026-09-30catalystTurnaround execution in Multiomics and core operations is the main recovery path into fiscal year-endHigh impact
Management said 2026 priorities are to transform Multiomics, strengthen commercial execution, optimize the operating footprint, and improve productivity through the Azenta Business System, while the 10-Q shows adequate liquidity at $564.8 million of cash, restricted cash, and marketable securities to fund the effort; still, the recovery has to offset weaker North America demand, Automated Stores rework, and inventory reserve pressure before the reset can re-rate [#8-K-2026-05-05] [#10-Q-2026-05-08] [#10-K-2025-12-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology